Shattuck Labs
- Country
- 🇺🇸United States
- Ownership
- Public
- Established
- 2016-01-01
- Employees
- 75
- Market Cap
- $168M
- Website
- http://www.shattucklabs.com
Clinical Trials
5
Trial Phases
1 Phases
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (5 trials with phase data)• Click on a phase to view related trials
Phase 1b Study of SL-172154 Administered with Combination Agent(s) in Subjects with Ovarian Cancers
- Conditions
- Platinum-resistant Ovarian CancerPlatinum-Resistant Fallopian Tube CarcinomaEpithelial Ovarian CancerPlatinum-Resistant Primary Peritoneal CarcinomaFallopian Tube CancerOvarian CancerPrimary Peritoneal Carcinoma
- Interventions
- Drug: Pegylated Liposomal Doxorubicin + SL-172154
- First Posted Date
- 2022-08-02
- Last Posted Date
- 2025-02-11
- Lead Sponsor
- Shattuck Labs, Inc.
- Target Recruit Count
- 86
- Registration Number
- NCT05483933
- Locations
- 🇺🇸
University of Arkansas for Medical sciences, Little Rock, Arkansas, United States
🇺🇸City of Hope, Duarte, California, United States
🇺🇸Robert H.Lurie ComprehensiveCancer Center, Northwestern University, Chicago, Illinois, United States
Phase 1 Study of Shattuck Labs (SL)-172154 in Subjects with MDS or AML
- Conditions
- Acute Myeloid LeukemiaMyelodysplastic Syndromes
- Interventions
- First Posted Date
- 2022-03-11
- Last Posted Date
- 2025-02-11
- Lead Sponsor
- Shattuck Labs, Inc.
- Target Recruit Count
- 106
- Registration Number
- NCT05275439
- Locations
- 🇺🇸
City of Hope, Duarte, California, United States
🇺🇸UCLA Medical Center-Bowyer Oncology Center, Los Angeles, California, United States
🇺🇸Yale Cancer Center, New Haven, Connecticut, United States
Ph1 Study of SL-172154 Administered Intratumorally in Subjects With Squamous Cell Carcinoma of the Head and Neck or Skin
- Conditions
- Squamous Cell Carcinoma of Head and NeckCutaneous Squamous Cell Carcinoma
- First Posted Date
- 2020-08-06
- Last Posted Date
- 2025-02-24
- Lead Sponsor
- Shattuck Labs, Inc.
- Target Recruit Count
- 5
- Registration Number
- NCT04502888
- Locations
- 🇺🇸
University of California, Los Angeles, Los Angeles, California, United States
🇺🇸Dana-Farber Cancer Institute, Boston, Massachusetts, United States
🇺🇸University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, United States
Phase 1 Study of SL-172154 (SIRPα-Fc-CD40L) in Subjects With Ovarian Cancer
- Conditions
- Ovarian CancerFallopian Tube CancerPrimary Peritoneal Carcinoma
- Interventions
- First Posted Date
- 2020-05-28
- Last Posted Date
- 2025-01-30
- Lead Sponsor
- Shattuck Labs, Inc.
- Target Recruit Count
- 27
- Registration Number
- NCT04406623
- Locations
- 🇺🇸
City of Hope, Duarte, California, United States
🇺🇸START Midwest, Grand Rapids, Michigan, United States
🇺🇸University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, United States
SL-279252 (PD1-Fc-OX40L) in Subjects With Advanced Solid Tumors or Lymphomas
- Conditions
- Non Small Cell Lung CancerUrothelial CarcinomaSquamous Cell Carcinoma of the AnusSquamous Cell Carcinoma of the CervixSquamous Cell Carcinoma of the SkinRenal Cell CarcinomaHodgkin LymphomaMismatch Repair Deficient or MSI-High Solid TumorsSquamous Cell Carcinoma of the Head and NeckGastric Adenocarcinoma
- Interventions
- First Posted Date
- 2019-03-28
- Last Posted Date
- 2025-04-02
- Lead Sponsor
- Shattuck Labs, Inc.
- Target Recruit Count
- 49
- Registration Number
- NCT03894618
- Locations
- 🇺🇸
The Sarah Cannon Research Institute, Nashville, Tennessee, United States
🇺🇸The University of Texas MD Anderson Cancer Center, Houston, Texas, United States
🇧🇪Leuven Cancer Institute, Leuven, Belgium
News
Shattuck Labs Secures $103 Million to Advance First-in-Class DR3 Antibody SL-325 Through Phase 2 Trials
Shattuck Labs raised up to $103 million in an oversubscribed private placement led by OrbiMed to fund development of SL-325, a potential first-in-class DR3 blocking antibody for autoimmune diseases.
Biotech Industry Faces Wave of Strategic Layoffs as Companies Prioritize Efficiency and Pipeline Focus
Major pharmaceutical and biotech companies including Pfizer, Johnson & Johnson, Fate Therapeutics, and Generation Bio are implementing workforce reductions as part of industry-wide financial restructuring efforts.
Shattuck Labs' SL-325 Demonstrates Strong Safety Profile in Pre-Clinical IBD Study
Shattuck Labs' SL-325, a DR3 blocking antibody, showed no adverse effects at doses up to 100 mg/kg in non-human primate toxicology studies, marking a significant milestone for inflammatory bowel disease treatment.
Shattuck Labs Announces Key Milestones for SL-325 Program Targeting Inflammatory Diseases
Shattuck Labs anticipates GLP toxicology study data readout for SL-325, a DR3 blocking antibody, in Q1 2025, supporting its development for inflammatory diseases.
Shattuck Labs Prioritizes SL-325, a DR3 Antagonist, for Inflammatory Bowel Disease
Shattuck Labs discontinues the clinical program for SL-172154 after modest survival improvements in TP53m AML and HR-MDS patients compared to azacitidine monotherapy.